UNSPSC 51391603: Amrinone or inamrinone

This classification denotes a vasodilating agent and phosphodiesterase inhibitor with the molecular formula C10H9N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JUT23379TN, chemically known as 5-amino-(3,4-bipyridin)-6(1h)-one but generally known as amrinone, which bears US NIH Compound Identifier 3698. European Medicines Agency schedules Amrinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05493MIG.

UNSPSC 51391603 Amrinone or inamrinone is a Commodity code for a specific cardiac inotropic agent used in acute heart failure treatment, yet the recent solicitation activity under this code shows a significant mismatch with the code's nominal scope. The single recent opportunity posted to this code — Seminole County, Florida's IFB60459723LAS — solicits Naloxone and Safe Drug Deactivation Systems, pharmaceutical products unrelated to amrinone. This mismatch suggests either a data-coding error in the state or local procurement system or that the code is being applied outside its intended pharmaceutical class. State and local governments typically procure amrinone through standing health department contracts or pharmacy cooperative purchasing vehicles rather than competitive sealed-bid processes, yet the underlying code receives minimal recent activity in the state and local market.

Seminole County's Naloxone and Safe Drug Deactivation Systems procurement (IFB60459723LAS, due July 26, 2023) is the only recent opportunity identifiable under this code. The county sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with an initial two-year contract term and one-year renewal option. Vendors were required to submit electronic bids including all shipping and delivery costs, meet E-Verify compliance, and maintain standard commercial insurance. While the opportunity nominally tags to this amrinone code, the actual scope represents overdose-reversal and drug-disposal services rather than cardiac pharmaceuticals. The persistent coding mismatch and lack of other recent opportunities suggest limited near-term activity under this Commodity code in the state and local space, or that genuine amrinone procurement occurs through channels not captured in public solicitation data.